Causes of Rotavirus Vaccine Failure in Zambian Children

This study is currently recruiting participants.
Verified June 2013 by Centre for Infectious Disease Research in Zambia
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Roma Chilengi, Centre for Infectious Disease Research in Zambia
ClinicalTrials.gov Identifier:
NCT01886833
First received: June 22, 2013
Last updated: NA
Last verified: June 2013
History: No changes posted
  Purpose

Zambia recently introduced routine infant immunization against rotavirus - the most important cause of severe gastroenteritis and diarrhoea mortality in children. Although vaccines like Rotarix are a cost effective tool against infectious diseases, live oral vaccines can be less immunogenic and efficacious in developing world settings as compared with industrialized countries. Reasons behind this phenomenon are not well understood, but may relate to continued maternal antigen exposure and high level maternal immunity that is passed to the foetus/newborn transplacentally and/or through breast milk.

Therefore, three arising hypotheses include: (i) high-level rotavirus-specific maternal immunity (in the form of anti-rotavirus breast-milk IgA and transplacental serum IgG) is a major contributor to failed seroconversion following infant vaccination. (ii) Malnutrition negatively impacts infant immunity and increases the risk of post-vaccination rotavirus gastroenteritis. (iii) Introduction of rotavirus vaccine will alter the molecular epidemiology of circulating rotavirus strains detected in vaccinated children presenting with severe diarrhea.

To address these hypotheses, the proposed study will recruit a prospective cohort of 420 mother-infant pairs. These will be enrolled at the time of vaccination and followed for up to four years. Baseline immunological status will be ascertained and seroconversion rates determined a month after full immunization. Incident rotavirus gastroenteritis will be monitored in the vaccinated infants whenever episodes of diarrhoea occur; through this surveillance, the sero-strains of rotaviruses causing disease will be tracked over the four year period. Contributions of HIV infection both in mothers and infants, vitamin A and zinc deficiency, weight for age Z-scores as well as mid upper arm circumference will also be assessed. Knowledge gained from this study will inform future interventional trials on strategies to improve rotavirus vaccine effectiveness in the developing world.


Condition
Diarrhoea

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 42 Months
Official Title: An Observational Study to Evaluate Causes of Rotavirus Vaccine Failure in Zambian Children in the Context of Routine Immunization Services

Resource links provided by NLM:


Further study details as provided by Centre for Infectious Disease Research in Zambia:

Primary Outcome Measures:
  • Proportion of immunized infants exposed to high breast milk anti-rotavirus immunoglobulin-A who fail to seroconvert [ Time Frame: 1 month following full immunization ] [ Designated as safety issue: No ]

    The primary exposure in this cohort is maternal IgA status, as we believe breast milk IgA is the most critical factor in failed vaccination, and maternal IgA has previously been estimated to be either high level (approximately 55%) or undetectable or low level (approximately 45%).

    We will collect maternal serum and breast-milk IgA at the time of vaccination and then measure infant anti-rotavirus-specific serum IgA levels 1 month following the second dose of Rotarix™ (GlaxoSmithKline) rotavirus vaccine.


  • Proportion of immunized infants exposed to transplacentally-acquired, rotavirus-specific, infant serum IgG who fail to sero-convert. [ Time Frame: 1 month after full immunisation ] [ Designated as safety issue: No ]

    The co-primary exposure in this cohort is transplacentally acquired anti-rotavirus immunoglubulin-G.

    We will collect infant serum at baseline before any vaccination and then measure the levels of anti-rotavirus-specific serum IgG and will also obtain the same at 1 month following the second dose of Rotarix™ rotavirus vaccine.


  • Proportion of immunized infants exposed to maternal HIV infection who fail to seroconvert [ Time Frame: 1 month following full immunisation ] [ Designated as safety issue: No ]
    To evaluate whether maternal HIV infection (as well as level of CD4 count) affects infant vaccine take, we will collect the maternal HIV status, (and CD4 count if +ve). We will then correlate the maternal HIC status and CD4 count levels to infant zero conversion at 1 month after the two vaccine doses.


Secondary Outcome Measures:
  • Proportion of immunized infants with low micronutrient levels (as indicated by serum zinc and vitamin A), who fail to seroconvert [ Time Frame: 1 month after full immunization ] [ Designated as safety issue: No ]
    To evaluation whether nutritional status affects vaccine take, we will assess the immunized infant's nutritional status as indicated by serum level of zinc and vitamin A. These will be correlated to seroconversion results.


Other Outcome Measures:
  • Sero-epidemiology of breakthrough rotavirus infection in immunized infants [ Time Frame: 42 months ] [ Designated as safety issue: No ]

    Determination of genotype in every rotavirus causing severe gastroenteritis will be done each time stool samples are collected for diarrhoea. Patients presenting with any diarrhoea will be tested for rotavirus and staged clinically (by Vesicary score). Those with severe disease (e.g., Vesikari >11/20) will be processed for genotype. Thus, we will identify the number of rotavirus cases following vaccination as well as identify the strain in those with severe disease.

    This will allow for "wild type versus vaccine"strain mismatch evaluation. We anticipate that the circulating strains in the community will change in response to vaccine pressure at the population level. However, when interpreting reasons for vaccine failure, it is critically important to evaluate strain mismatch because the way to approach this type of breakthrough disease is dramatically different than if there is breakthrough infection to vaccine strain rotavirus.



Biospecimen Retention:   Samples With DNA

Blood samples for immunogenicity testing will be analyzed in batches.

Stool samples for rotavirus extraction will also be stored and analyzed in batches.


Estimated Enrollment: 420
Study Start Date: April 2013
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
Mother-Infant Pair

The study will involve consenting mother-infant pairs from Kamwala health facility in Lusaka where the Maternal Child Health (MCH). Those generally interested will be invited to the research clinic, where more detailed information about the study is offered. Motivated mothers will be recruited and taken through the written informed consent process by the study nurse.

Enrolled mother-infant pairs will undergo baseline procedures as earlier described. They will then be followed prospectively until about December 2016. They will be expected to come to the clinic for scheduled visits at baseline, 1, 3, 12, 15 and 42 months. They will be urged to come to the clinic for unscheduled visit should the infant be unwell at any time, and particularly each time the infant experiences diarrhoea.


  Hide Detailed Description

Detailed Description:

The study will be conducted at Kamwala health facility in Lusaka where the Maternal Child Health (MCH) and antiretroviral therapy (ART) clinics as well as the CIDRZ Kamwala Research Unit are co-located. Kamwala has a catchment population of over 10,000 with approximately 30 new infants presenting to MCH each month with 6-14 week (DPT-HiB-Hep) immunisation rates above 95%. Mother-infant pairs will be approached during the initial visit to MCH by the study clinic assistant or peer counsellor with information about this study in the local language of choice. Those generally interested will be invited to the research clinic which is close by, for more detailed information during which motivated mothers will be recruited and taken through the written informed consent process by the study nurse. For illiterate participants, an independent, literate individual will witness and validate the informed consent process. A specific log will be maintained to show information on dates and numbers of those invited to the study, reasons for refusal documented.

A senior research nurse, study nurse, and clinical research assistant will be responsible for informed consent and enrolment procedures under the supervision of the investigator. A paediatrician will be available for hands-on consultation when needed.

Cohort Follow-up. Enrolled mothers will be asked to complete demographic and behavioural questionnaires, a participant locator form, and undergo phlebotomy and mechanical expression of breast-milk at the enrolment visit for determination of anti-rotavirus IgG and IgA (in serum and breast-milk). Infants will have a baseline anti-rotavirus IgA and IgG antibodies determined to ascertain baseline exposure to wild-type and transplacental immunoglobulin followed by a second serum IgA determination one month following completion of rotavirus vaccination (at approximately 14-20 weeks).

Infants will then be followed quarterly in-clinic for the remainder of the study and will also make interim clinic visits if the child has diarrhoea. At each visit, the child will be weighed, height measured, and anthropometrics taken, including skin fold for subcutaneous body fat and mid upper arm circumference. During any symptomatic interim visits, assessments will be made of disease severity (by Vesikari scale) and a sample of stool will be collected for determination of rotavirus antigen and genotype if rotavirus positive. The patient will also be sent home with a diarrhoea diary to be completed over the following two weeks. Following identification of an child with severe gastroenteritis, an age-matched control from within the cohort (without recent gastroenteritis) will be brought in for measurement of Vitamin A and serum zinc levels. Children with gastroenteritis will be treated according to national guidelines (per WHO Integrated Management of Childhood Illness). If referral is required, the child will be referred to outpatient clinic, or in serious cases the University Teaching Hospital.

Study Procedures. Enrolled mothers will be asked to complete demographic and behavioural questionnaires, a participant locator form, and undergo phlebotomy and mechanical expression of breast-milk at the enrolment visit for determination of anti-rotavirus IgG and IgA (in serum and breast-milk). Infants will have a baseline anti-rotavirus IgA and IgG antibodies determined to ascertain baseline exposure to wild-type and transplacental immunoglobulin followed by a second serum IgA determination one month following completion of rotavirus vaccination (at approximately 14-20 weeks).

Infants will then be followed quarterly in-clinic for the remainder of the study and will also make interim clinic visits if the child has diarrhoea. At each visit, the child will be weighed, height measured, and anthropometrics taken, including skin fold for subcutaneous body fat and mid upper arm circumference.55-57 During any symptomatic interim visits, assessments will be made of disease severity (Vesikari scale58) and a sample of stool will be collected for determination of rotavirus antigen and genotype if rotavirus positive. The patient will also be sent home with a diarrhoea diary to be completed over the following two weeks. Following identification of an child with severe gastroenteritis, an age-matched control from within the cohort (without recent gastroenteritis) will be brought in for measurement of Vitamin A and serum zinc levels. Children with gastroenteritis will be treated according to national guidelines (per WHO Integrated Management of Childhood Illness). If referral is required, the child will be referred to outpatient clinic, or in serious cases the University Teaching Hospital.

Laboratory Methods.

  1. Detection of Rotavirus-specific IgA and IgG will occur by ELISA. Detection of rotavirus-specific IgA and IgG will occur by ELISA. Briefly, the procedure is as follows. Microplate wells (e.g., Nunc Immuno I) are incubated with purified viral antigen preparations, then washed with phosphate buffered saline with Tween detergent (PBS-T). Serum and breast-milk samples are diluted serially (in PBS-T containing 1% bovine serum albumin) and incubated in the coated microplates for 2 hours at 37oC then overnight at 4oC. Microplates are then washed and peroxidase-conjugated anti-human IgA or IgG goat antibodies (Sigma Immunochemicals) is added. The reaction is then terminated with H2SO4, and optical density is measured by EIA plate reader. All samples are assayed in duplicate against each viral antigen and against a control antigen. A test well was considered positive by its optical density at 450 nm, e.g., if it is greater than or equal to two times that of its own control. Specificity is controlled by including wells containing control antigen incubated in the absence of the sample, and sensitivity is checked by including wells containing viral antigen incubated in the presence of samples known to contain high titre of a particular rotavirus-specific immunoglobulin class.
  2. Detection of Rotavirus Antigen will occur by Rotaclone ELISA. Stool samples will be tested for rotavirus by ELISA (Rotaclone®, Meridian Biosciences) according to manufacturer's specifications. Briefly, sample will be brought to room temperature and diluted with buffered saline with 0.02% thimerosol. Diluted sample and enzyme conjugate are then incubated with a monoclonal antibody to the VP6 protein within the Rotaclone microplate. Substrate buffers containing urea peroxide and tetramethylbenzidine are then added, and the reaction is terminated with H2SO4. Spectrophotometric determination of result is then made by measuring absorbance at 450 nm against an air blank. Specimens with absorbance units (A450) greater than 0.150 are considered positive. Those with absorbance equal to or below 0.150 are considered negative.

3 Determination of Rotavirus VP7 Genotype. Viral RNA is extracted from a 10% suspension of rotavirus antigen-positive faecal material in PBS (pH 7.0) using TRIzolTM Reagent (GIBCO Life Technologies) according to the manufacturer's protocol. Viral RNA is then taken through RT-PCR as described earlier.

Extracted viral RNA is then taken through nested PCR utilizing primers which are complimentary to the 3' ends of both viral RNA strands within gene segment 9, which encodes viral protein 7 (VP7). These primers are used for first strand synthesis. Primer RVG9 and six serotype-specific primers (aBT1, aCT2, aET3, aDT4, aAT8, and aFT9) which are located in six variable regions on the gene 9 and correspond to G-serotypes 1, 2, 3, 4, 8 and 9, are used in second amplification. Briefly, 5 µl of RNA with 25 pmol of each primer Beg9 and End9 is denatured for 5 min at 97°C and cooled on ice. Thereafter, 8 µl of RT reaction mixture containing 1.5 µl of 10X PCR buffer (500 mM KCl, 100 mM Tris-HCl (pH 8.3), 2 µl of 25 mM MgCl2, 2 µl of 2.5 mM of each dATP, dCTP, dGTP and dTTP, 10 U AMV reverse transcriptase (Promega) and 20 U Rnasin ribonuclease inhibitor (Promega), is added to the sample-primer mixture and incubated at 42°C for 60 min. PCR buffer mixture (35 µl), containing 3.5 µl of 10X PCR buffer, 2 µl of 2.5 mM peach dATP, dCTP, dGTP and dTTP, 2.5 U Ampli Taq DNA polymerase (Perkin Elmer) and 27 µl of water are added to RT reaction. The reaction mixture is denatured at 94°C for 3 min, followed by 30 cycles (1 min at 94°C, 2 min at 42°C, 3 min at 72°C) and a final extension of 5 min at 72°C.

First-round PCR products (2 µl) are transferred to 48 µl of second PCR reaction mixture, containing 5 µl of 10X PCR buffer, 25 pmol each primers aBT1, aCT2, aET3, aDT4, aAT8, aFT9 and RVG9, 0.2 mM each dATP, dGTP, dCTP and dTTP, 2mM MgCl2, 2.5 U of Taq polymerase. Second-round cycling conditions are identical to first round, except that only 25 cycles are run. The PCR products are analyzed by gel electrophoresis to identify expected lengths of amplified VP7, allowing determination of genotype. Other primer sets, PCR conditions and/or sequencing is used to distinguish genotype when/if the initial primers fail.

4 Determination of VP4 Genotype. The strategy for PCR typing of gene 4 is identical, in principle, to that used for VP7.64 First strand synthesis (reverse transcription) takes advantage of highly conserved areas of VP4 utilizing primers Con2 and Con3 (Box 3), which are complimentary to the 3' ends of both viral RNA strands within gene segment 4. 1 to 5 µL of viral RNA is added to 0.5 ml microcentrifuge tubes containing 3.5 µl of dimethylsulfoxide (Sigma) in a final volume of 8.5 µl, and the samples are mixed and denatured at 97°C for 5 min. The samples are then cooled on ice for 5 min and collected by brief centrifugation. 13.5 µL of H20, 16 µL of deoxynucleoside triphosphates (1.25 mM each dATP, dGTP, dCTP, and dTTP), 5 µL 1OX buffer (100 mM Trishydrochloride [pH 8.3], 500 mM KCl) (Perkin-Elmer Cetus), 3.5 µL of 25 mM MgCl2, 2 µl of primer (containing 25 µM of each primer, Con 2 and Con 3), and 9 U reverse transcriptase is then added to each denatured dsRNA sample tube (to give a final reaction volume of 49 µ1) and incubated at 42oC for 60 minutes.

Following addition of 1 µL (1.9U) of Taq polymerase and 100 µL mineral oil, first-round PCR is carried out for 30 cycles (1 min 94oC, 2 min at 50oC, and 2 min at 72oC. A cooling cycle is used to bring the samples to 17OC at the completion of the experiment. The second-round typing reaction if performed using 0.5 to 5 µL of the first-round product (5 µL if no visible product; 0.5 µL if visible product) is mixed with 45 µL reaction mixture in a final volume of 50 µL. If less than 5 µL of first round product is added, the remaining volume, to complete 50 µL, is 10mM TrisHCl (pH 8.3)-2.5mM MgCl¬2. The reaction mixture is 19.5 µL water, 16 µL dNTPs, 5 µL 10X Buffer II, 3 µL 25 mM MgCl2, 1 µL of the primer cocktail (containing 20 µM each of Con3, 1T-1, 2T-1, 3T-1, and 4T-1), and 0.5 µL (2.5U) Taq. The samples are overlaid with mineral oil and taken through 25 rounds of PCR (same cycles as first round). The samples are then analyzed by gel electrophoresis and product size enables determination of VP4 genotype. Other primer sets and/or sequencing is used to distinguish genotype when/if the initial primers fail.

5 Determination of Vitamin A and Zinc levels: Serum samples will be evaluated for Vitamin A level by ELISA (e.g., Human Vitamin A, EIAAB) according to the manufacturer's instructions. Briefly, the microtitre plate provided in this kit has been pre-coated with an antibody specific to Vitamin A. Standards or samples are then added to the appropriate microtitre plate wells with a biotin-conjugated polyclonal antibody preparation specific for VA and Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then a tetramethylbenzidine substrate solution is added to each well. Only those wells that contain Vitamin A, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in colour. The enzyme-substrate reaction is terminated by the addition of a H2SO4 and the color change is measured spectrophotometrically at a wavelength of 450 nm. The concentration of VA in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Zinc levels will be measured from blood using assays such as Lampugnani's simple colorimetric method which uses a spectrophotometric method with chromogen 4-(2-pyridylazo) resorcinol sodium salt to measure serum zinc concentrations.

  Eligibility

Ages Eligible for Study:   6 Weeks to 15 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

The study will be conducted at Kamwala health facility in Lusaka where the Maternal Child Health (MCH) and antiretroviral therapy (ART) clinics as well as the CIDRZ Kamwala Research Unit are co-located. Kamwala has a catchment population of over 10,000 with approximately 30 new infants presenting to MCH each month with 6-14 week (DPT-HiB-Hep) immunisation rates above 95%. Mother-infant pairs will be approached during the initial visit to MCH by the study clinic assistant or peer counsellor with information about this study in the local language of choice. Those generally interested will be invited to the research clinic which is close by, for more detailed information during which motivated mothers will be recruited and taken through the written informed consent process by the study nurse. For illiterate participants, an independent, literate individual will witness and validate the informed consent process.

Criteria

Inclusion Criteria:

  • Mother willing to participate voluntarily and able to provide signed informed consent (with witness in the case of illiterate participant)
  • Infant eligible for rotavirus vaccine immunization as per national policy (male or female infant, 6-12 weeks old)
  • Mother willing to undergo study procedures, including questionnaires, HIV counselling and testing, CD4 testing, and provide breast milk and blood sample at enrolment.
  • Mother willing for child to undergo study procedures including full-course rotavirus vaccination, phlebotomy at enrolment and 1 month post-rotavirus vaccination, and presentation to clinic for collection of stool sample when infant has diarrhoea.
  • Plans to remain resident in the area and willing to come for scheduled visits for the duration of the study.

Exclusion Criteria:

  • Contraindication to rotavirus vaccination.
  • Previous administration of rotavirus vaccine to child.
  • Recent immunosuppressive therapy in child (including high-dose systemic corticosteroids).
  • History of ever receiving a blood transfusion or blood products, including immunoglobulins within the last 6 months, for mother and child.
  • Mother plans for herself or child to move away from the study catchment area within the next two years.
  • Any condition deemed by the study investigator to pose potential harm to the participants or jeopardize the validity of study results.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01886833

Contacts
Contact: Roma Chilengi, MD, MSc +260973724935 Roma.Chilengi@cidrz.org
Contact: Bradford M Guffey, MD, MSc +260 968666895 Brad.Guffey@cidrz.org

Locations
Zambia
Centre for Infectious Disease Research in Zambia Recruiting
Lusaka, Zambia, 10101
Contact: Roma Chilengi, MD, MSc    +2609173724935    Roma.Chilengi@cidrz.org   
Contact: Marcellina Hamikondo, BSc    +260977120736    Marcellina.Hamikondo@cidrz.org   
Principal Investigator: Roma Chilengi, MD, MSc         
Sponsors and Collaborators
Centre for Infectious Disease Research in Zambia
Investigators
Principal Investigator: Roma Chilengi, MD, MSc Centre for Infectious Disease Research in Zambia
  More Information

No publications provided

Responsible Party: Roma Chilengi, Dr, Centre for Infectious Disease Research in Zambia
ClinicalTrials.gov Identifier: NCT01886833     History of Changes
Other Study ID Numbers: ROVAS 01, 1R01AI099601-01
Study First Received: June 22, 2013
Last Updated: June 22, 2013
Health Authority: Zambia: Ministry of Health

Keywords provided by Centre for Infectious Disease Research in Zambia:
Rotavirus
Diarrhoea
Dmmunisation
Seroconversion
Breastmilk
HIV
Zinc
Vitamin A
Failure

Additional relevant MeSH terms:
Diarrhea
Signs and Symptoms, Digestive
Signs and Symptoms

ClinicalTrials.gov processed this record on April 17, 2014